ANI PHARMACEUTICALS, INC Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share
ANI PHARMACEUTICALS, INC (ANIP) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share of $0.04 per share for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare · last filed 2014-02-28
- ANI PHARMACEUTICALS, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2013-09-30 was $0.02, a 97.22% decline year-over-year.
- ANI PHARMACEUTICALS, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2013-06-30 was $0.00.
- ANI PHARMACEUTICALS, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2012-09-30 was $0.72.
- ANI PHARMACEUTICALS, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2012-06-30 was $0.00.
- ANI PHARMACEUTICALS, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2013 was $0.04.
- ANI PHARMACEUTICALS, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2012 was $0.00.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.04 10-K · filed 2014-02-28 | |||
| 2013-09-30 | $0.02 10-Q · filed 2013-11-07 | $0.04 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $0.00 10-Q · filed 2013-08-09 | $0.00 10-Q · filed 2013-08-09 | ||
| 2012-12-31 | $0.00 10-K · filed 2014-02-28 | |||
| 2012-09-30 | $0.72 10-Q · filed 2013-11-07 | $66.99 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $0.00 10-Q · filed 2013-08-09 | $157.47 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |